Skip to main content
Premium Trial:

Request an Annual Quote

EPI in Canadian Breast Cancer Biomarker Collaboration

NEW YORK (GenomeWeb News) – Expression Pathology will collaborate with the Tom Baker Cancer Centre in Alberta, Canada, to identify breast cancer metastasis biomarkers, EPI said today.
 
The project is being funded with CAD$300,000 ($288,000) from the Alberta Cancer Board.
 
EPI said it will use its tissue proteomics technologies to study archived formalin-fixed breast cancer tissue samples taken from patients treated at the cancer center. The company’s Liquid Tissue sample preparation and Director laser microdissection technologies will enable in-depth mass spectrometry analysis, the firm said.
 
“Our project with EPI will strive to identify proteins in primary tumor tissue that may serve as biomarkers of the early stages of metastasis at the molecular level,” Anthony Magliocco, director of pathology at the center and an associate professor of medicine at the University of Calgary, said in a statement.
 
“Our aim is to develop valuable tissue protein assays that can aid patient treatment decisions and to identify new therapeutic targets and companion diagnostics to those targets,” said EPI CEO Casimir Eitner in a statement.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.